EMA Recommends Changing Marketing Authorization for Avapritinib for Systemic Mastocytosis
source: pixabay.com

EMA Recommends Changing Marketing Authorization for Avapritinib for Systemic Mastocytosis

According to a recent article, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) is now recommending changing the marketing authorization for avapritinib, which is used…

Continue Reading EMA Recommends Changing Marketing Authorization for Avapritinib for Systemic Mastocytosis
Rare Disease Day 2022: This Rare Mom Shares Her IgA Nephropathy Patient Experience on TikTok
source: pixabay.com

Rare Disease Day 2022: This Rare Mom Shares Her IgA Nephropathy Patient Experience on TikTok

Judy was diagnosed at age 45 with the rare disease IgA nephropathy in 2019. The diagnosis changed her life forever. IgA nephropathy is difficult to diagnose until it has progressed,…

Continue Reading Rare Disease Day 2022: This Rare Mom Shares Her IgA Nephropathy Patient Experience on TikTok

Studies Show Favorable Results For PARP Inhibitors in the Treatment of Advanced Ovarian Cancer

Dr. Rachel Grisham MSK ovarian cancer section head discussed clinical trials investigating PARP inhibitors for ovarian cancer patients. The event was a round table discussion and interview for Targeted Oncology.…

Continue Reading Studies Show Favorable Results For PARP Inhibitors in the Treatment of Advanced Ovarian Cancer
Rare Black History: A Childhood Home of Rare Disease Patient Henrietta Lacks Was Unknowingly Demolished
source: pixabay.com

Rare Black History: A Childhood Home of Rare Disease Patient Henrietta Lacks Was Unknowingly Demolished

According to a story from the Baltimore Sun, a childhood home of Henrietta Lacks - a Black woman often dubbed "the mother of modern medicine" - was unknowingly demolished just…

Continue Reading Rare Black History: A Childhood Home of Rare Disease Patient Henrietta Lacks Was Unknowingly Demolished
Bylvay Recommended for Progressive Familial Intrahepatic Cholestasis in Europe
source: pixabay.com

Bylvay Recommended for Progressive Familial Intrahepatic Cholestasis in Europe

In the past, treatment for progressive familial intrahepatic cholestasis (PFIC) was symptomatic or surgical, meaning that there weren't too many treatment options for this patient population. This all changed with…

Continue Reading Bylvay Recommended for Progressive Familial Intrahepatic Cholestasis in Europe
Soleo Health will Administer Primary Hyperoxaluria Type 1 Treatment at Infusion Centers Across The Country
Photo by Robina Weermeijer on Unsplash

Soleo Health will Administer Primary Hyperoxaluria Type 1 Treatment at Infusion Centers Across The Country

Soleo Health has just announced that they have been provided access to lumasiran by Alnylam Pharmaceuticals. This access will allow the company to administer the treatment to patients diagnosed with…

Continue Reading Soleo Health will Administer Primary Hyperoxaluria Type 1 Treatment at Infusion Centers Across The Country